Mapping the intellectual structure of the research of omalizumab in chronic spontaneous urticaria : A bibliometric analysis
© 2024 The Author(s)..
Background: The guidelines for treating chronic spontaneous urticaria (CSU) recommend using the IgE-targeted biologic omalizumab in patients with antihistamine-refractory disease.
Objective: Our aim was to present a bibliometric review of publications related to omalizumab and CSU over the past 2 decades.
Methods: Relevant publications from 2003 to 2022 were extracted from the Science Citation Index-Expanded (SCI-EXPANDED) database in the Web of Science Core Collection database as of January 8, 2023. We utilized CiteSpace (version 6.1.R3), VOSviewer (version 1.6.18), and the R package (version 4.2.1) to analyze and visualize the data. The R package bibliometrix (version 4.2.1) was also used.
Results: Between 2003 and 2022, a total of 566 articles on omalizumab and CSU were published. Since 2014, there has been a rapid increase in publication output. According to the collaboration network, the most influential country, institute, and scholar were the United States, Charité Universitätsmedizin Berlin, and Marcus Maurer, respectively. The study identified the Journal of Allergy and Clinical Immunology: In Practice as the most productive journal and the Journal of Allergy and Clinical Immunology as the most cocited journal. The analysis of key words revealed the presence of high-frequency terms such as angioedema, IgE, treatment, anti-IgE, asthma, and atopic dermatitis. Moreover, recent studies in this area have concentrated mainly on biomarkers, dupilumab, and coronavirus 2019 (COVID-19).
Conclusion: There has been a growing interest in the use of omalizumab in CSU in recent years. The current trending topics in this research are the identification of biomarkers and the development of new mAbs for the treatment of CSU.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. Global - 3(2024), 2 vom: 21. März, Seite 100222 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yao, Yuxu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bibliometric study |
|---|
| Anmerkungen: |
Date Revised 01.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jacig.2024.100222 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369095979 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369095979 | ||
| 003 | DE-627 | ||
| 005 | 20240301232914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacig.2024.100222 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM369095979 | ||
| 035 | |a (NLM)38419687 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yao, Yuxu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mapping the intellectual structure of the research of omalizumab in chronic spontaneous urticaria |b A bibliometric analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Author(s). | ||
| 520 | |a Background: The guidelines for treating chronic spontaneous urticaria (CSU) recommend using the IgE-targeted biologic omalizumab in patients with antihistamine-refractory disease | ||
| 520 | |a Objective: Our aim was to present a bibliometric review of publications related to omalizumab and CSU over the past 2 decades | ||
| 520 | |a Methods: Relevant publications from 2003 to 2022 were extracted from the Science Citation Index-Expanded (SCI-EXPANDED) database in the Web of Science Core Collection database as of January 8, 2023. We utilized CiteSpace (version 6.1.R3), VOSviewer (version 1.6.18), and the R package (version 4.2.1) to analyze and visualize the data. The R package bibliometrix (version 4.2.1) was also used | ||
| 520 | |a Results: Between 2003 and 2022, a total of 566 articles on omalizumab and CSU were published. Since 2014, there has been a rapid increase in publication output. According to the collaboration network, the most influential country, institute, and scholar were the United States, Charité Universitätsmedizin Berlin, and Marcus Maurer, respectively. The study identified the Journal of Allergy and Clinical Immunology: In Practice as the most productive journal and the Journal of Allergy and Clinical Immunology as the most cocited journal. The analysis of key words revealed the presence of high-frequency terms such as angioedema, IgE, treatment, anti-IgE, asthma, and atopic dermatitis. Moreover, recent studies in this area have concentrated mainly on biomarkers, dupilumab, and coronavirus 2019 (COVID-19) | ||
| 520 | |a Conclusion: There has been a growing interest in the use of omalizumab in CSU in recent years. The current trending topics in this research are the identification of biomarkers and the development of new mAbs for the treatment of CSU | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Omalizumab | |
| 650 | 4 | |a VOSviewer | |
| 650 | 4 | |a bibliometric study | |
| 650 | 4 | |a chronic spontaneous urticaria | |
| 650 | 4 | |a knowledge map | |
| 700 | 1 | |a Liu, Zhichen |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Jiang |e verfasserin |4 aut | |
| 700 | 1 | |a Jiao, Qingqing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. Global |d 2022 |g 3(2024), 2 vom: 21. März, Seite 100222 |w (DE-627)NLM345686632 |x 2772-8293 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2024 |g number:2 |g day:21 |g month:03 |g pages:100222 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacig.2024.100222 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2024 |e 2 |b 21 |c 03 |h 100222 | ||